Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy.
AVXS-101
SMA1
gene replacement
gene therapy
health outcomes
quality of life
spinal muscular atrophy
Journal
Pediatric pulmonology
ISSN: 1099-0496
Titre abrégé: Pediatr Pulmonol
Pays: United States
ID NLM: 8510590
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
22
06
2018
accepted:
04
11
2018
pubmed:
15
12
2018
medline:
29
1
2020
entrez:
15
12
2018
Statut:
ppublish
Résumé
Spinal Muscular Atrophy type 1 (SMA1) is a rare genetic neuromuscular disease where 75% of SMA1 patients die/require permanent-ventilation by 13.6 months. This study assessed the health outcomes of SMA1 infants treated with AVXS-101 gene replacement therapy. Twelve genetically confirmed SMA1 infants with homozygous deletions of the SMN1 gene and two SMN2 gene copies received a one-time intravenous proposed therapeutic dose of AVXS-101 in an open label study conducted between December 2014 and 2017. Patients were followed for 2-years post-treatment for outcomes including (1) pulmonary interventions; (2) nutritional interventions; (3) swallow function; (4) hospitalization rates; and (5) motor function. All 12 patients completed the study. Seven infants did not require noninvasive ventilation (NIV) by study completion. Eleven patients had stable or improved swallow function, demonstrated by the ability to feed orally; 11 patients were able to speak. The mean proportion of time hospitalized was 4.4%; the mean unadjusted annualized hospitalization rate was 2.1 (range = 0, 7.6), with a mean length of stay/hospitalization of 6.7 (range = 3, 12.1) days. Eleven patients achieved full head control and sitting unassisted and two patients were walking independently. AVXS-101 treatment in SMA1 was associated with reduced pulmonary and nutritional support requirements, improved motor function, and decreased hospitalization rate over the follow-up period. This contrasts with the natural history of progressive respiratory failure and reduced survival. The reduced healthcare utilization could potentially alleviate patient and caregiver burden, suggesting an overall improved quality of life following gene replacement therapy. ClinicalTrials.gov number, NCT02122952.
Sections du résumé
BACKGROUND
Spinal Muscular Atrophy type 1 (SMA1) is a rare genetic neuromuscular disease where 75% of SMA1 patients die/require permanent-ventilation by 13.6 months. This study assessed the health outcomes of SMA1 infants treated with AVXS-101 gene replacement therapy.
METHODS
Twelve genetically confirmed SMA1 infants with homozygous deletions of the SMN1 gene and two SMN2 gene copies received a one-time intravenous proposed therapeutic dose of AVXS-101 in an open label study conducted between December 2014 and 2017. Patients were followed for 2-years post-treatment for outcomes including (1) pulmonary interventions; (2) nutritional interventions; (3) swallow function; (4) hospitalization rates; and (5) motor function.
RESULTS
All 12 patients completed the study. Seven infants did not require noninvasive ventilation (NIV) by study completion. Eleven patients had stable or improved swallow function, demonstrated by the ability to feed orally; 11 patients were able to speak. The mean proportion of time hospitalized was 4.4%; the mean unadjusted annualized hospitalization rate was 2.1 (range = 0, 7.6), with a mean length of stay/hospitalization of 6.7 (range = 3, 12.1) days. Eleven patients achieved full head control and sitting unassisted and two patients were walking independently.
CONCLUSIONS
AVXS-101 treatment in SMA1 was associated with reduced pulmonary and nutritional support requirements, improved motor function, and decreased hospitalization rate over the follow-up period. This contrasts with the natural history of progressive respiratory failure and reduced survival. The reduced healthcare utilization could potentially alleviate patient and caregiver burden, suggesting an overall improved quality of life following gene replacement therapy.
TRIAL REGISTRATION
ClinicalTrials.gov number, NCT02122952.
Identifiants
pubmed: 30548438
doi: 10.1002/ppul.24203
pmc: PMC6590370
doi:
Substances chimiques
SMN1 protein, human
0
Survival of Motor Neuron 1 Protein
0
Banques de données
ClinicalTrials.gov
['NCT02122952']
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
179-185Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2018 The Authors. Pediatric Pulmonology Published by Wiley Periodicals, Inc.
Références
Neuromuscul Disord. 2018 Feb;28(2):103-115
pubmed: 29290580
Neuromuscul Disord. 2009 Dec;19(12):805-12
pubmed: 19846309
Pediatr Pulmonol. 2002 Jul;34(1):16-22
pubmed: 12112792
PLoS One. 2013;8(2):e56945
pubmed: 23451114
N Engl J Med. 2017 Nov 2;377(18):1723-1732
pubmed: 29091570
J Neurosci Rural Pract. 2016 Apr-Jun;7(2):223-7
pubmed: 27114652
Pediatr Pulmonol. 2019 Feb;54(2):179-185
pubmed: 30548438
Neurology. 2014 Aug 26;83(9):810-7
pubmed: 25080519
Ann Neurol. 2017 Dec;82(6):883-891
pubmed: 29149772
Expert Rev Clin Pharmacol. 2014 Jan;7(1):53-65
pubmed: 24308784
Arch Dis Child. 2011 May;96(5):426-32
pubmed: 20573738
Chest. 2006 Dec;130(6):1879-86
pubmed: 17167012
Orphanet J Rare Dis. 2017 Jul 4;12(1):124
pubmed: 28676062
Immunity. 2004 Jun;20(6):769-83
pubmed: 15189741
Pharmacoecon Open. 2019 Jun;3(2):205-213
pubmed: 30182345
Orphanet J Rare Dis. 2016 May 04;11(1):58
pubmed: 27145956
Food Nutr Bull. 2004 Mar;25(1 Suppl):S37-45
pubmed: 15069918
N Engl J Med. 2017 Nov 2;377(18):1713-1722
pubmed: 29091557
Health Qual Life Outcomes. 2016 Apr 07;14:56
pubmed: 27052007
Neuromuscul Disord. 2018 Mar;28(3):197-207
pubmed: 29305137
Nat Biotechnol. 2010 Mar;28(3):271-4
pubmed: 20190738
Neurology. 2007 Jan 16;68(3):198-201
pubmed: 17224573
Chest. 2017 May;151(5):962-965
pubmed: 27989614
Hum Mol Genet. 2014 Sep 1;23(17):4559-68
pubmed: 24722206
Natl Vital Stat Rep. 2012 Oct 10;61(6):1-51
pubmed: 24984457
BMC Neurol. 2017 Apr 4;17(1):68
pubmed: 28376816
Eur J Hum Genet. 2012 Jan;20(1):27-32
pubmed: 21811307
Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13104-9
pubmed: 17664425
Orphanet J Rare Dis. 2017 Aug 18;12(1):141
pubmed: 28821278
Neuromuscul Disord. 2017 May;27(5):419-427
pubmed: 28302390
Neuromuscul Disord. 2017 May;27(5):428-438
pubmed: 28237437